Xipere is a brand name of Triamcinolone acetonide, a prescription medicine. The FDA NDC Directory lists 1 Xipere product in 1 strength and form.

Bausch and Lomb Inc holds the FDA application for Xipere (NDA211950, approved October 22, 2021).

Is there a generic or store brand of Xipere?

Yes. The FDA NDC Directory lists 25 other products with the same active ingredients, strength and form as a Xipere product, 17 of them generic. Ask your pharmacist whether one is right for you.

Xipere (Triamcinolone acetonide): maker, FDA approval and generic versions

Official data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the NDC Directory, Drugs@FDA, the official labels and recall reports; pharmacy costs come from the Centers for Medicare & Medicaid Services (CMS). Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or switch any medicine, including a switch between a brand and a generic.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Xipere?: Xipere is a brand name of Triamcinolone acetonide, a prescription medicine. The FDA NDC Directory lists 1 Xipere product in 1 strength and form.
Who makes Xipere?: Bausch and Lomb Inc holds the FDA application for Xipere (NDA211950, approved October 22, 2021).
Is there a generic or store brand of Xipere?: Yes. The FDA NDC Directory lists 25 other products with the same active ingredients, strength and form as a Xipere product, 17 of them generic. Ask your pharmacist whether one is right for you.
Has Xipere been recalled?: No recall linked to Xipere products (by their NDC code or label) appears in the FDA enforcement reports we use.

What Xipere is

Each Xipere product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.

Triamcinolone acetonide · prescription medicine

Strength and form	Product names	Same medicine, other names	Label
triamcinolone acetonide 40 mg/mL injection, suspension (ophthalmic)	Xipere	25 products, 17 companies	DailyMed

Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Triamcinolone acetonide →

FDA approval

NDA: New Drug Application: how a new (usually brand-name) medicine is approved.

FDA applications of Xipere products (Drugs@FDA)
Application	Holder	First approved	Products
NDA211950	Bausch and Lomb Inc	October 22, 2021	1

Companies that list Xipere

The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Xipere products.

Bausch & Lomb Incorporated1 product

Recalls

No recall linked to Xipere products (by their NDC code or label) appears in the FDA enforcement reports.

Sources

NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026

Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.

Report an error → · Information for medicine makers

Xipere